ASFA refreshes therapeutic apheresis guidance across 93 fact sheets
The American Society for Apheresis has released the tenth special issue of its Journal of Clinical Apheresis guidance, expanding and refining the evidence-based framework for therapeutic apheresis across human disease. The update preserves the familiar fact-sheet format introduced in 2007, but the content now spans 93 fact sheets and 183 graded, categorized indications, making it one of the most comprehensive reference sources for clinicians who use apheresis in daily practice.
This is not a niche manual for a single disorder. It is a cross-disciplinary clinical map for a procedure that may be used very differently depending on the disease biology, the urgency of treatment, and the strength of supporting evidence. By organizing the literature into succinct disease-specific summaries, the committee gives clinicians a structured way to judge where apheresis is established, where it remains selective, and where evidence is still too thin to support routine use.
The tenth edition keeps the same basic architecture as earlier updates, but the accumulation of evidence has forced continued recalibration. Two new fact sheets were added, and several existing indications changed in category or grade. In a field where treatment decisions often hinge on time-sensitive pathology, those shifts matter because they alter whether apheresis should be considered standard, conditional, or reserved for narrowly defined scenarios.
Evidence grading remains the core of the update
The committee’s central task is straightforward in concept and difficult in execution: review the literature, judge the quality of evidence, and translate that evidence into practical recommendations. The new edition continues to use systematic review and evidence-based methods to grade support for each indication. That approach is especially important in a procedural therapy where randomized trials are not always feasible and many disease states rely on observational data, mechanistic reasoning, and expert consensus.
Apheresis occupies a unique place in medicine because its value often depends on whether removing, replacing, or selectively filtering blood components changes the trajectory of a disease quickly enough to matter. In antibody-mediated disorders, for example, the biological rationale can be immediate: if circulating pathogenic factors are driving tissue injury, physically removing them may stabilize the clinical course while slower immunomodulatory therapies take effect. In lipid disorders, the logic is different but equally direct; reducing a harmful circulating burden may be relevant when vascular risk is extreme or refractory to standard therapy. The fact sheets are built to reflect those differences rather than force every disease into the same therapeutic mold.
One sentence captures the practical burden on clinicians: apheresis is not one treatment, but a family of interventions with distinct mechanisms and different levels of evidentiary support.
183 indications, but not a single level of confidence
The tenth edition’s 183 graded and categorized indications show how uneven the evidence base remains. Some uses of therapeutic apheresis are backed by a more established literature, while others depend on narrower experience or lower-grade data. The committee’s categorization framework exists precisely because clinicians need more than a list of diseases; they need a judgment about whether the procedure is appropriate in a given clinical context, and how strong that judgment is.
That distinction has bedside consequences. Apheresis can be resource-intensive, logistically complex, and dependent on specialized staff and equipment. It also carries procedural considerations that may be especially relevant in medically fragile patients. When evidence is strong, the threshold for use is lower. When evidence is weak or mixed, the procedure must compete with other treatments on the basis of plausibility, urgency, and risk.
The fact-sheet model helps compress that complexity into a format clinicians can actually use. Each sheet summarizes the evidence for a specific disease entity or medical condition, allowing quick comparison across indications while preserving the nuance of the underlying literature. The tenth edition keeps that design intact because it remains clinically useful: the question is rarely whether apheresis exists, but whether it should be deployed now, later, or not at all.
Two new fact sheets expand the scope of the manual
The addition of two new fact sheets signals continued growth in the catalog of conditions reviewed by the committee. The update does not specify the disease names in the abstract, but their inclusion indicates that the evidence base has advanced enough to justify formal evaluation and categorization within the ASFA framework. In a document of this kind, new fact sheets are more than editorial additions; they are markers of where practice is evolving and where clinicians may soon need clearer direction.
Several older indications also changed in category or grade. Those revisions are often the most clinically consequential part of a major update because they may shift how a clinician weighs apheresis against alternative strategies. A change in category can alter whether a therapy is considered routine, selective, or unsupported for a given disease. A change in grade can signal stronger evidence, persistent uncertainty, or a need for caution when extrapolating from limited data.
A reference designed for specialty care, not general shorthand
Because therapeutic apheresis spans neurology, hematology, nephrology, and other disciplines, the committee’s synthesis functions as a shared language across specialties. The tenth edition is intended to serve as a key resource guiding utilization of therapeutic apheresis in human disease, and its value lies in that cross-specialty consistency. Clinicians who order, supervise, or refer for the procedure need a common framework for interpreting evidence, particularly when the same intervention may be used for very different pathophysiologic reasons.
The continued reliance on concise fact sheets reflects a pragmatic editorial choice. Dense narrative reviews can be difficult to apply at the point of care. A structured evidence summary is easier to operationalize, especially when treatment decisions must be made quickly and with incomplete information. The ASFA format does not eliminate uncertainty, but it organizes it in a way that can be acted on.
This edition also reinforces a broader clinical truth: procedural therapies need periodic reclassification as the literature matures. Apheresis indications are not static. They shift as new data emerge, as disease definitions change, and as competing therapies improve. The tenth special issue keeps pace with that process by preserving the evidence-based grading system while expanding the number of conditions reviewed.
What clinicians gain from the tenth special issue
For bedside practice, the new special issue offers something more durable than a single recommendation. It provides a reproducible method for deciding when apheresis belongs in the treatment plan, how confident the field is in that decision, and where future evidence is still needed. The document’s size alone — 93 fact sheets and 183 indications — reflects the breadth of modern apheresis practice, but its real value lies in how it sorts that breadth into usable clinical judgments.
The update does not close the book on debate. It codifies where the evidence currently stands and where the discipline remains dependent on careful judgment. Future revisions will almost certainly revisit several indications again, because the use of apheresis depends on an evidence base that is still evolving in many disease states. For now, the tenth edition gives clinicians a current, graded reference for deciding when apheresis is justified, when it is conditional, and when the literature still does not support routine use.